ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Shionogi as a shareholder, today announced new ...

Detailed phase 3 results suggest the two-drug combination of Gilead Sciences’ lenacapavir and Merck & Co.’s islatravir has ...

Gilead Sciences & Merck announce investigational once-weekly oral HIV treatment regimen of islatravir and lenacapavir maintained virological suppression in adults with HIV who swi ...

As the world marks World AIDS Day on Dec. 1, infectious disease expert Anthony Fauci, MD, and his colleague Greg Folkers, MS, MPH, highlight advances made in the treatment and prevention of HIV that ...

Studies revealing the real-world impact of disruptions to the US President’s Emergency Plan for AIDS Relief (PEPFAR) and important advances in long-acting HIV prevention and treatment were announced ...

A drug used to treat HIV that has also shown promise in preventing infections is not a cure for those already infected, as claimed in social media posts. Apart from rare and dangerous stem cell ...

ViiV Healthcare will present a broad range of clinical and real-world data at AIDS 2026, highlighting progress across its integrase strand transfer inhibitor portfolio, including long-acting medicines ...

The world may look back on 2024 as a pivotal time in the fight against AIDS — the start of a revolution in the global biomedical response to HIV using long-acting antiretroviral medicines. Young women ...

A new national clinical trial found HIV drug regimens that do not include efavirenz are effective as first-line antiretroviral therapy. The finding is important for patients who are not eligible for ...

UNAIDS chief calls for ‘radical change’ as aid cuts gut HIV clinics and treatment worldwide.